Cooperative Agreement UG1CA304955
Award Date 8/5/25
Completion Date 7/31/31
Dollars Obligated $2.5M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Madison, WI 53715, USA
Similar Awards
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $716,623 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Chicago. The award will fund the creation of a multi-tissue DNA methylation data resource using samples from the Genotype-Tissue Expression (GTEx) project. This resource will enable researchers to study variability in human epigenomes and the genetic and environmental...
- The National Cancer Institute (NCI) awarded a $825,857 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Health Research, Inc. at Roswell Park Comprehensive Cancer Center. The goal of this 5-year award is to catalyze collaboration across the Cancer Immunoprevention Network (CIP-NET) and manage, integrate, and disseminate the data and resources generated by the network. Key objectives include fostering a collaborative research community, providing...
- This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports efforts by a Columbia University researcher to develop and implement NCI-sponsored cancer clinical trials at the NCI-designated Herbert Irving Comprehensive Cancer Center (HICCC). The $193,926 award, with a project period from September 1, 2025 to August 31, 2030, will enable the researcher to: (1) develop novel HICCC investigator-led trials for...
- This $5,041,790 cooperative agreement award from the National Cancer Institute (NCI), under the Cancer Centers Support Grants program (CFDA 93.397), will fund research projects at the University of California, San Francisco (UCSF) to improve cancer health disparities. The key products and services to be delivered include: Three translational cancer health disparities research projects focused on meningioma, prostate cancer, and breast cancer. The projects aim to evaluate the interplay of...
- This $850,611 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the University of Texas Southwestern Medical Center to investigate the role of tRNA modifications in regulating mitochondrial activity and cancer metastasis in renal cell carcinoma. The project aims to examine how overexpression of dihydrouridine synthase enzymes, which introduce dihydrouridine modifications in tRNAs, impacts the translation of...
- This Cooperative Agreement award of $922,755.00 from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Massachusetts Medical School (UMASS Medical) aimed at understanding the role of tRNA modification and translational remodeling in cancer progression and metastasis. The project will use advanced RNA mass spectrometry, sequencing, and ribosome profiling techniques to comprehensively catalog tRNA modification dynamics...
- This $462,092 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is focused on investigating novel immune checkpoint targets for the topical immunoprevention of keratinocytic skin cancer. The award is held by the University of Arizona and will run from August 1, 2025 to July 31, 2027. The key objectives of the project are to 1) use human samples to identify novel immune checkpoint proteins that are upregulated early in the skin...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $1,583,640 to the University of California, San Diego (UC San Diego) from June 23, 2025 to May 31, 2028 to advance spatial metabolomics research for cancer. The project aims to develop and apply the METASPACE open-source software platform to enable data analysis and interpretation of large, complex spatial metabolomics datasets generated through imaging mass spectrometry techniques....
- This Cooperative Agreement award of $556,865.00 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Trustees of Tufts College to conduct research on "Stiffness-Mediated Genetic Selection of Cells". The project aims to investigate how the mechanical properties of a cell's substrate can drive the evolution of cell phenotypes and genotypes over sustained culture periods. The research will quantify how cell behaviors like growth, motility, and...